V

Varian

Tech-enabled radiation oncology hardware and software

Vice President, Informatics Solutions Portfolio

Full-Time
$240k - $330k+ Commission
Expert
Bachelor's, MBA
Remote in USA
Remote
ProductProduct Management
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • At least 15 years of progressive leadership experience in diagnostics, in-vitro diagnostics, healthcare IT, digital health, or medical technology, with significant responsibility for global product, platform, or portfolio strategy.
  • Deep, hands-on expertise in diagnostic informatics, healthcare IT, digital platforms, data analytics, or AI-enabled solutions; Core Lab and enterprise lab workflows are strongly preferred.
  • Proven success building and scaling global platforms or solutions portfolios, including competing against top-tier industry players.
  • Demonstrated ability to envision and build new businesses, not just manage incremental product extensions.
  • A strong track record of partnering with R&D, software, data science, and digital teams to deliver differentiated, profitable solutions.
  • A bachelor's degree is required.
Responsibilities
  • Own the global strategy, lifecycle management, and P&L mindset for the Diagnostics Informatics portfolio, from market insight and concept definition through launch, scale, and end-of-life decisions.
  • Define and execute a multi-year informatics roadmap spanning platforms, applications, data services, AI and advanced analytics, interoperability, and digital solutions.
  • Establish Informatics as a growth engine with clear value propositions independent of, yet complementary to, instruments, reagents, automation, and services.
  • Set portfolio priorities and trade-offs across regions, balancing global platform scale with local market, regulatory, and workflow needs.
  • Define differentiated competitive positioning for diagnostics informatics and translate competitive intelligence, market trends, and ecosystem shifts into portfolio and investment strategies.
  • Lead the development of competitive playbooks, platform narratives, and enterprise-level selling strategies for large, strategic Informatics opportunities.
  • Anticipate and shape the future of diagnostic informatics, including data monetization, AI-enabled decision support, enterprise analytics, and ecosystem partnerships.
  • Serve as the global subject-matter expert on diagnostic informatics, understanding laboratorians, clinicians, hospital executives, health system leadership, IT, and digital transformation stakeholders.
  • Use direct customer engagement, market research, and real-world data to refine portfolio direction and business strategy.
  • Represent the voice of the customer in defining how informatics delivers measurable clinical, operational, and financial outcomes.
  • Define global go-to-market strategies for Informatics, including segmentation, targeting, positioning, pricing architecture, and launch excellence.
  • Partner with commercial leaders to influence enterprise deal strategy, bundling and unbundling approaches, and Informatics-led value selling in competitive accounts.
  • Equip commercial teams with messaging, sales tools, economic value narratives, and scientific evidence to win consistently.
  • Provide customer and market requirements to guide Informatics R&D, platform architecture, and data strategy.
  • Lead trade-off decisions balancing customer value, scalability, cybersecurity, regulatory requirements, and speed to market.
  • Serve as a senior partner to R&D and Digital teams across development, launch, and post-launch optimization.
  • Lead structured global launches that drive rapid adoption, competitive displacement, and profitable growth.
  • Own post-launch performance, ensuring Informatics solutions meet commercial, customer, and financial expectations over time.
  • Continuously optimize the portfolio based on performance data, customer feedback, and market evolution.
  • Lead, develop, and inspire a high-performing global Informatics portfolio and product marketing organization.
  • Operate as a core member of the Diagnostics and Digital leadership teams, shaping integrated business, platform, and growth strategy.
  • Drive alignment and execution across a complex global matrix organization, influencing at the executive level.
Desired Qualifications
  • An MBA or advanced degree is strongly preferred.
  • Core Lab and enterprise lab workflows are strongly preferred.
  • Experience leading and developing global, cross-functional teams within a matrixed organization.

About the company

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Wellness Program
  • 401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Varex Imaging Corporation
Sep 14th, 2026
About Us | Varex Imaging Corporation

We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster

MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.